Long-term follow-up from a phase Ib trial in newly diagnosed and previously treated patients with advanced melanoma showed that 40 percent of patients were alive three years after starting Keytruda (pembrolizumab), with similar 36-month overall survival rates in both groups.
Collecting images of suspicious-looking skin growths and sending them off-site for specialists to analyze is as accurate in identifying skin cancers as having a dermatologist examine them in person, a new study shows.
